

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 3, 2025

NK-92

RRID:CVCL_2142

Type: Cell Line

Proper Citation

(RRID:CVCL_2142)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2142

Proper Citation: (RRID:CVCL_2142)

Sex: Male

Defining Citation: [PMID:8152260](#), [PMID:9118301](#), [PMID:9573023](#), [PMID:10365666](#), [PMID:10803505](#), [PMID:11454312](#), [PMID:12850795](#), [PMID:16827800](#), [PMID:18424763](#), [PMID:19194464](#), [PMID:20454443](#), [PMID:21052088](#), [PMID:21570725](#), [PMID:25586472](#), [PMID:26559813](#), [PMID:30054012](#), [PMID:31126350](#), [PMID:31160637](#), [PMID:34349345](#), [PMID:36610812](#)

Comments: Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep exome analysis., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line.

Category: Cancer cell line

Name: NK-92

Synonyms: NK92, Natural Killer-92, NK-92.05, Neukoplast, aNK

Cross References: BTO:BTO_0003287, CLO:CLO_0008177, EFO:EFO_0022517, AddexBio:C0003026/NA, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2407, BCRC:60414, BioSample:SAMN03471836, CCRID:4201HUM-CCTCC00052, CCTCC:GDC0052, Cell_Model_Passport:SIDM01143, Cosmic:1534874, Cosmic:1542071, Cosmic:2025326, Cosmic:2390215, Cosmic:2785204, DSMZ:ACC-488, DSMZCellDive:ACC-488, GEO:GSM472001, IPD-IMGT/HLA:13674, Lonza:1093, Wikidata:Q17149636

ID: CVCL_2142

Record Creation Time: 20250131T202119+0000

Record Last Update: 20250131T203927+0000

Ratings and Alerts

No rating or validation information has been found for NK-92.

Warning: Discontinued: ATCC; PTA-6670

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep exome analysis., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line. **Warning:** Discontinued: BCRC; 60414

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep exome

analysis., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 391 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Peng Y, et al. (2024) Non-IL-2-blocking anti-CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti-CTLA-4 therapy. *International journal of cancer*, 154(7), 1285.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Wang QM, et al. (2024) Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis. *Molecular cancer research : MCR*, 22(2), 125.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng. *Immunity*, 57(6), 1360.

Xu L, et al. (2024) A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. *Cell reports. Medicine*, 5(5), 101511.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Pérez M, et al. (2024) Microbiota-Derived Short-Chain Fatty Acids Boost Antitumoral Natural Killer Cell Activity. *Journal of clinical medicine*, 13(13).

Geng S, et al. (2024) Co-Colorectal cancer stem cells employ the FADS1/DDA axis to evade NK cell-mediated immunosuppression after co-cultured with NK cells under hypoxia. *International immunopharmacology*, 143(Pt 3), 113535.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. *Cancer cell*, 42(6), 985.

Deng R, et al. (2024) ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/?-catenin/PD-L1 axis. *iScience*, 27(4), 109533.

Zuo P, et al. (2023) Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas. *Frontiers in immunology*, 14, 1145706.

Luo BH, et al. (2023) Screening of Lymphoma Radiotherapy-Resistant Genes with CRISPR Activation Library. *Pharmacogenomics and personalized medicine*, 16, 67.

Bai X, et al. (2023) CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. *Nature communications*, 14(1), 1247.

Kim H, et al. (2023) CD19/CD22 bispecific chimeric antigen receptor?NK?92 cells are developed and evaluated. *Oncology letters*, 25(6), 236.

Xiao X, et al. (2023) Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. *Frontiers in immunology*, 14, 1113303.

Wu Y, et al. (2023) SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF??B signaling and enhancing nature killer cell?mediated tumor surveillance. *Experimental and therapeutic medicine*, 25(5), 195.

Juncker T, et al. (2023) The Prodigious Potential of mRNA Electrotransfer as a Substitute to Conventional DNA-Based Transient Transfection. *Cells*, 12(12).

Neo SY, et al. (2023) Effects of *Leea indica* leaf extracts and its phytoconstituents on natural killer cell-mediated cytotoxicity in human ovarian cancer. *BMC complementary medicine and therapies*, 23(1), 79.

Kennedy PR, et al. (2023) A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. *Frontiers in immunology*, 14, 1060905.

Susek KH, et al. (2023) Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy. *Cancer immunology, immunotherapy* : CII, 72(5), 1153.